研究疾病:
|
精神分裂症
|
研究疾病代码:
|
|
Target disease:
|
Schizophrenia
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
探索性研究/预试验
Pilot clinical trial
|
研究目的:
|
采用口服12周中药大柴温胆汤配方颗粒,干预服用非典型抗精神病药引起代谢综合征的精神分裂症患者,科学评估其对代谢综合征的疗效及副作用,及其对精神症状的影响,为中医药干预精神分裂症患者代谢综合征这一临床难题,提供科学依据。
|
Objectives of Study:
|
The prescription granules of Dachai Wendan Decoction, a 12 week oral Chinese medicine, are used to treat the schizophrenic patients with metabolic syndrome caused by atypical antipsychotics. The efficacy and side effects of the granule on the metabolic syndrome and its influence on the mental symptoms are evaluated scientifically, which provide scientific basis for the intervention of Chinese medicine on the metabolic syndrome of schizophrenic patients.
|
药物成份或治疗方案详述:
|
所有患者保持原有的抗精神病药物种类和剂量不变,在此基础上:
研究组:大柴温胆汤免煎中药配方颗粒,每日1剂,冲服。药物组成:半夏、姜竹茹、枳实、陈皮、甘草、茯苓、黄连、柴胡、黄芩、白芍、大黄、生姜、大枣,由华润三九医药有限公司根据配方统一提供配方颗粒。
对照组:服大柴温胆汤免煎中药配方颗粒模拟剂(由华润三九医药有限公司提供,与大柴温胆汤配方颗粒在质量和口味上一致,但无有效成分),每日1剂,冲服。
疗程均12周。
|
Description for medicine or protocol of treatment in detail:
|
For all patients, the original types and doses of antipsychotic drugs are unchanged, on this basis:
DWD Group: Dachai Wendan Decoction as a traditional Chinese medicine formula granules is received,1 dose per day. Drug composition: Pinellia ternate, jiangzhuru, Zhishi, Chenpi, liquorice, Poria cocos, Coptis, bupleurum, Scutellaria, white peony, rhubarb, ginger, jujube, formula particles are provided by China Resources Sanjiu Pharmaceutical Co., Ltd. according to the formula.
Control group: take one dose of dachaiwendan Decoction (provided by China Resources Sanjiu Pharmaceutical Co., Ltd., consistent with the quality and taste of dachaiwendan decoction, but without effective ingredients) every day.
The course of treatment was 12 weeks.
|
纳入标准:
|
①符合ICD-10关于精神分裂症的诊断标准;
②符合《中国2型糖尿病防治指南(2017年版)》关于代谢综合征的诊断标准:
1)腹型肥胖(即中心型肥胖):腰围男性≥90 cm,女性≥85 cm;
2)高血糖:空腹血糖≥6.1 mmol/L 或糖负荷后2 h血糖≥7.8 mmol/L和(或)已确诊为糖尿病并治疗者;
3)高血压:血压≥130/85 mmHg 及(或)已确认为高血压并治疗者;
4)空腹TG≥1.70 mmol/L;
5)空腹HDL-C<1.04 mmol/L;
以上具备三项或更多项即可诊断代谢综合征。
③服用非典型抗精神病药治疗,剂量稳定3个月以上,且病情稳定不需要调整抗精神病药物剂量;
④年龄在18-65岁之间。
|
Inclusion criteria
|
1. Subjects who met the ICD-10 diagnostic criteria for schizophrenia;
2. Patients who met the diagnostic criteria of metabolic syndrome in Chinese guidelines for the prevention and treatment of type 2 diabetes (2017 Edition):
(1) Abdominal obesity (central obesity): waist circumference of male >= 90 cm, female >= 85 cm;
(2) Hyperglycemia: fasting blood glucose >= 6.1 mmol / L or blood glucose >= 7.8 mmol / L 2 h after glucose load and / or diabetes mellitus diagnosed and treated;
(3) Hypertension: blood pressure >= 130 / 85 mmHg and / or confirmed hypertension and treated;
(4) Fasting TG >= 1.70 mmol / L;
(5) Fasting HDL-C < 1.04 mmol / L;
Three or more of the above can be used to diagnose metabolic syndrome.
3. Patients taking atypical antipsychotics had a stable dose for more than 3 months, and their condition was stable, so it was not necessary to adjust the dose of antipsychotics;
4. Patients aged between 18 and 65 years.
|
排除标准:
|
①伴有冲动、自杀、自伤行为风险者;
②有严重肝肾功能损害、心功能不全或其他急性并发症及严重感染者;
③共病酒、药等物质滥用者;
④合并有其他内分泌疾病如库欣综合症等,或服用大量激素所致向心性肥胖者。
⑤Ⅰ型糖尿病、继发性高血压、家族性血脂异常者;
⑥对中草药成分过敏者;
⑦除代谢综合征外的实验室检查指标异常且有临床意义者。
⑧妊娠期和哺乳期患者,或3个月内有怀孕计划者。
|
Exclusion criteria:
|
1. Patients with impulsive, suicidal and self injurious behaviors;
2. Patients with severe liver and kidney damage, cardiac insufficiency or other acute complications and severe infection;
3. Co infected patients with alcohol, drugs and other substance abuse;
4. Patients with other endocrine diseases such as Cushing's syndrome, or Cardiotropic obesity caused by taking a lot of hormones.
5. Patients with type I diabetes, secondary hypertension and familial dyslipidemia;
6. Patients who are allergic to Chinese herbal ingredients;
7. Patients with abnormal laboratory indexes and clinical significance except metabolic syndrome.
8. Patients during pregnancy and lactation, or those with pregnancy planning within 3 months.
|
研究实施时间:
Study execute time:
|
从From
2020-07-01
至To
2022-12-31
|
征募观察对象时间:
Recruiting time:
|
从From
2020-12-31
至To
2022-12-31
|